- Home
- XNCR vs BCRX Comparison
XNCR vs BCRX Comparison
Compare XNCR & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- BCRX
- Stock Information
- Founded
- XNCR 1997
- BCRX 1986
- Country
- XNCR United States
- BCRX United States
- Employees
- XNCR N/A
- BCRX N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XNCR Health Care
- BCRX Health Care
- Exchange
- XNCR Nasdaq
- BCRX Nasdaq
- Market Cap
- XNCR 1.5B
- BCRX 1.7B
- IPO Year
- XNCR 2013
- BCRX 1994
- Fundamental
- Price
- XNCR $24.10
- BCRX $7.49
- Analyst Decision
- XNCR Strong Buy
- BCRX Strong Buy
- Analyst Count
- XNCR 8
- BCRX 5
- Target Price
- XNCR $35.50
- BCRX $15.60
- AVG Volume (30 Days)
- XNCR 569.4K
- BCRX 2.4M
- Earning Date
- XNCR 11-06-2024
- BCRX 11-04-2024
- Dividend Yield
- XNCR N/A
- BCRX N/A
- EPS Growth
- XNCR N/A
- BCRX N/A
- EPS
- XNCR N/A
- BCRX N/A
- Revenue
- XNCR $85,164,000.00
- BCRX $412,579,000.00
- Revenue This Year
- XNCR N/A
- BCRX $37.24
- Revenue Next Year
- XNCR $86.53
- BCRX $19.30
- P/E Ratio
- XNCR N/A
- BCRX N/A
- Revenue Growth
- XNCR N/A
- BCRX 29.92
- 52 Week Low
- XNCR $15.31
- BCRX $4.03
- 52 Week High
- XNCR $26.84
- BCRX $8.88
- Technical
- Relative Strength Index (RSI)
- XNCR 70.71
- BCRX 48.27
- Support Level
- XNCR $22.60
- BCRX $6.92
- Resistance Level
- XNCR $23.86
- BCRX $8.25
- Average True Range (ATR)
- XNCR 0.83
- BCRX 0.46
- MACD
- XNCR 0.05
- BCRX -0.05
- Stochastic Oscillator
- XNCR 96.85
- BCRX 45.71
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.